Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Prevalence, incidence and risk factors of tamoxifen‐related non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

Published:2020-04-07 Issue:6 Volume:40 Page:1344-1355
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Lee Bora¹^ORCID,Jung Eun‐Ae²,Yoo Jeong‐Ju³^ORCID,Kim Sang Gyune³^ORCID,Lee Cheon‐Beom³,Kim Young Seok³^ORCID,Jeong Soung Won⁴^ORCID,Jang Jae Young⁴^ORCID,Lee Sae Hwan⁵^ORCID,Kim Hong Soo⁵^ORCID,Jun Baek Gyu⁶^ORCID,Kim Young Don⁶^ORCID,Cheon Gab Jin⁶

Affiliation:

1. Department of Statistics Graduate School of Chung‐Ang University Seoul Republic of Korea

2. Medical Library Soonchunhyang University Bucheon Hospital Bucheon Korea

3. Division of Gastroenterology and Hepatology Department of Internal Medicine Soonchunhyang University School of Medicine Bucheon Hospital Bucheon Korea

4. Division of Gastroenterology and Hepatology Department of Internal Medicine Soonchunhyang University School of Medicine Seoul Korea

5. Division of Gastroenterology and Hepatology Department of Internal Medicine Soonchunhyang University School of Medicine Cheonan Korea

6. Department of Internal Medicine University of Ulsan College of Medicine Gangneung Asan Hospital Gangneung‐si Korea

Funder

Soonchunhyang University

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14434

Reference46 articles.

1. A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors

2. Tamoxifen for early breast cancer: an overview of the randomised trials

3. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

4. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial

5. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-metabolic causes of steatotic liver disease;Metabolism and Target Organ Damage;2023-10-26

2. Changes in m6A in Steatotic Liver Disease;Genes;2023-08-19

3. Mitochondrial alterations in fatty liver diseases;Journal of Hepatology;2023-02

4. Fatostatin inhibits SREBP2-mediated cholesterol uptake via LDLR against selective estrogen receptor α modulator-induced hepatic lipid accumulation;Chemico-Biological Interactions;2022-09

5. Tamoxifen induced hepatic steatosis in high-fat feeding rats through SIRT1-Foxo1 suppression and LXR-SREBP1c activation;Toxicology Research;2022-07-22